Research Progress of Next Generation Sequencing in Acute Leukemia --Review.
10.19746/j.cnki.issn.1009-2137.2023.02.046
- Author:
Wei-Ling CHEN
1
,
2
;
Zhong GUO
1
,
2
;
Zhi-Zhong HOU
1
,
2
;
Yi-Jian CHEN
3
Author Information
1. Gannan Medical College
2. Ganzhou 341000, Jiangxi Province, China.
3. Department of Hematology, The First Affiliated Hospital of Gannan Medical College, Ganzhou 341000, Jiangxi Province, China. E-mail：chenyj2005@163.com.
- Publication Type:Journal Article
- Keywords:
acute leukemia;
minimal residual disease;
mixed phenotype acute leukemia;
next generation sequencing;
acute lymphoblastic leukemia;
acute myelogenous leukemia
- MeSH:
Humans;
High-Throughput Nucleotide Sequencing;
Leukemia, Myeloid, Acute/genetics*;
Acute Disease;
Mutation;
Recurrence;
Neoplasm, Residual/genetics*
- From:
Journal of Experimental Hematology
2023;31(2):612-615
- CountryChina
- Language:Chinese
-
Abstract:
With the advent of precision medicine, next-generation sequencing (NGS) is playing an increasingly important role in clinical oncology diagnosis and treatment with its advantages of high sensitivity, high accuracy, high efficiency and operability. NGS reveals the genetic characteristics of acute leukemia(AL) patients by screening for specific disease-causing genes to identify occult as well as complex genetic mutations in patients with AL, leading to early diagnosis and targeted drug therapy for AL patients, as well as to predict disease recurrence by detecting mnimal residual disease (MRD) and analyzing mutated genes to determine patient prognosis. NGS plays an increasingly important role in the diagnosis, treatment and prognosis assessment in AL, providing a direction for the pursuit of precision medicine. This paper reviews the research progress of NGS in AL.
